Please try another search
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee’s Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
Name | Age | Since | Title |
---|---|---|---|
Sandeep Laumas | 54 | 2018 | Independent Director |
John L. Ryan | 80 | 2018 | Independent Director |
Shalabh K. Gupta | 50 | 2016 | Founder, Chairman, CEO & President |
Ravindra L. Mehta | - | - | Member of Scientific Advisory Board |
Pablo E. Pergola | - | - | Member of Scientific Advisory Board |
Myles Selig Wolf | 52 | - | Member of Scientific Advisory Board |
Gaurav Aggarwal | 51 | 2023 | Independent Director |
Glenn Matthew Chertow | - | - | Member of Scientific Advisory Board |
Saraswati Kenkare-Mitra | 56 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review